Find out all about your favorite commercial!

Advertisers

Advertisers of the Opdivo + Yervoy TV Spot, 'Combination Immunotherapy Treatment'

Opdivo + Yervoy TV commercial - Combination Immunotherapy Treatment
Opdivo

IntroductionOpdivo is a brand name for the drug nivolumab, which is a type of immunotherapy used to treat certain types of cancer. It is manufactured by Bristol-Myers Squibb and was first approved by...

What the Opdivo + Yervoy TV commercial - Combination Immunotherapy Treatment is about.

Opdivo + Yervoy TV commercial - Combination Immunotherapy Treatment

The Opdivo + Yervoy TV Spot is an advertisement for a new combination immunotherapy treatment, which is aimed at treating certain types of cancers. The commercial starts with a woman sitting in a dimly lit room, looking out the window, her expression conveying a sense of hopelessness and resignation. The voiceover then explains that for many people living with cancer, this sense of despair is all too familiar.

But there is hope, the commercial goes on to explain. The Opdivo + Yervoy combination treatment is an immunotherapy that works with the body's own immune system to help fight cancer cells. The commercial shows images of the drugs at work, as well as happy patients who are shown living their lives cancer-free after the treatment.

The Opdivo + Yervoy TV spot is a compelling reminder that, while cancer remains a devastating and life-threatening disease, modern medicine continues to make strides in treating it. For those who are struggling with cancer, this TV spot is a powerful message of hope and possibility, showing that there are always new and innovative treatments on the horizon which can help lead to a cure.

Opdivo + Yervoy TV commercial - Combination Immunotherapy Treatment produced for Opdivo was first shown on television on August 30, 2020.

Frequently Asked Questions about opdivo + yervoy tv spot, 'combination immunotherapy treatment'

Combination immunotherapy counters several immunosuppressive elements in the tumor microenvironment and activates multiple steps of the cancer-immunity cycle.

Can immunotherapy cure stage 4 cancer? While immunotherapy doesn't cure stage 4 cancer, it can improve the quality and longevity of your life.

The combination of nivolumab and ipilimumab works as a systemic treatment to promote an immune response, with the goals of: Controlling melanoma and shrinking tumors anywhere in the body. Treating symptoms of melanoma. Helping patients live longer.

OPDIVO is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).

Treating Multiple Kinds of Cancer Immunotherapy has shown success in 15 different types of cancers including lung cancer, head and neck cancer, bladder cancer, kidney cancer, and Hodgkin lymphoma.

The idea behind the combination is that by killing malignant cells, the chemotherapy generates an inflammatory response that draws T cells towards the cancer. Pembrolizumab can then disable the PD-1 checkpoint pathway that protects tumours from an immune attack.

Some immunotherapy treatments help the immune system stop or slow the growth of cancer cells. Others help the immune system destroy cancer cells or stop the cancer from spreading to other parts of the body. The different types of immunotherapy include: Monoclonal antibodies and immune checkpoint inhibitors.

Results from several clinical trials suggest that, for some people with earlier-stage cancers, a short course of treatment with immune checkpoint inhibitor may be all they need to eliminate their cancer.

80% of those who took the immunotherapy drug survived after 5 years, whereas survival rates from standard treatments are 36–68%.

Opdivo, approved for both melanoma and lung cancer, is priced at $12,500 a month, or about $150,000 for a year of treatment; patients take the drug until disease progression or unacceptable toxicity. Keytruda, approved for the treatment of metastatic melanoma, will cost about the same.

For patients receiving Opdivo plus Opdualag, the 12-, 24- and 36-month progression-free survival rates were 48%, 38% and 31%, respectively. Overall survival rates were 77%, 62% and 54%, at these time points, respectively, with a 48-month overall survival rate of 52%.

The longer a patient continues treatment, the higher the health care costs become - both to the patient and to the health care system - and there is ongoing risk of immune-related side effects.

Videos

Watch Opdivo + Yervoy TV Commercial, 'Combination Immunotherapy Treatment'

Unfortunately we were unable to find any suitable videos in the public domain. Perhaps the video of this TV commercial has not been preserved. If you know the link to this commercial, you can send it to us using a special form.

Products

Products Advertised

Opdivo Opdivo + Yervoy
TV commercials

Similar commercials

FixMeStick TV Spot, 'The Easiest Way to Remove Viruses'
Opdivo TV Spot, 'Most Prescribed Immunotherapy'
2018 Volkswagen Atlas TV Spot, 'Parents' [T1]
BarkBox TV Spot, 'Holiday Box'
998 November 30, 2014
Opdivo + Yervoy TV Spot, 'A Chance for More Sparks'
Opdivo + Yervoy TV Spot, 'A Chance to Live Longer'
Opdivo + Yervoy TV Spot, 'A Chance for More Sparks: Live Longer'
Kohl's TV Spot, 'Mamá modelo' canción de Crooked Man
Neulasta Onpro TV Spot, 'The Day After Chemo: Copay Card'
Opdivo + Yervoy TV Spot, 'A Chance for More Horizons'
Neulasta Onpro TV Spot, 'Rather Be Home - Onpro'
Priceline.com TV Spot, 'When Family's on the Line'